Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Active, not recruiting · NCT02788981 · Registry updated 2025-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2025-06-10 | NCT02788981 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Chicago | 326 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Froedtert and The Medical College of Wisconsin | Milwaukee | United States | 21 |
| NorthShore University HealthSystem | Evanston | United States | 25 |
| University of Alabama - Birmingham | Birmingham | United States | 1 |
| University of Chicago | Chicago | United States | 312 |